Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Table 2 Immune event outcomes

Outcome	n*	%*
Flare¹	13	28.9
irAE²	20	44.4
Gastrointestinal	7	15.5
Pulmonary	5	11.1
Dermatologic	4	8.9
Endocrine	3	6.7
Rheumatologic	3	6.7
Other	2	4.4
Any event (flare or irAE)	27	60.0
Multiple events	9	20.0
Severe events (grade 3 +)	8	17.8
Death (grade 5 event)	1	2.2
Flare/irAE requiring systemic steroids	21	46.7
Unfavorable cancer response (M/PG/D)	37	82.2
Median time to unfavorable cancer response, median (95% CI) days	139	(98, 193)

irAE, immune related adverse event; M, mixed response; PG, progressive disease; D, death
*Unless otherwise specified
¹Flare of the underlying rheumatologic disease as defined by clinical documentation of an exacerbation of a patient’s underlying rheumatologic disease
²New-onset immune related adverse event distinct from pre-existing disease

ISSN: 2520-1026